Objective: In response to a need for better sepsis diagnostics, several new gene expression classifiers have been recently published, including the 11-gene "Sepsis MetaScore, " the "FAIM3-to-PLAC8" ratio, and the Septicyte Lab. We performed a systematic search for publicly available gene expression data in sepsis and tested each gene expression classifier in all included datasets. We also created a public repository of sepsis gene expression data to encourage their future reuse. Data Sources: We searched National Institutes of Health Gene Expression Omnibus and EBI ArrayExpress for human gene expression microarray datasets. We also included the Glue Grant trauma gene expression cohorts. Study Selection: We selected clinical, time-matched, whole blood studies of sepsis and acute infections as compared to healthy and/or noninfectious inflammation patients. We identified 39 datasets composed of 3,241 samples from 2,604 patients. Data Extraction: All data were renormalized from raw data, when available, using consistent methods.
T here is no rapidly available gold standard test that can determine whether a patient with systemic inflammation has an underlying infection. Missed diagnoses of sepsis lead to delayed treatment and increased mortality, whereas inappropriate antibiotics increase antibiotic resistance and can lead to complications (1) (2) (3) . There is thus an urgent and unmet need for new diagnostics that can separate patients with noninfectious inflammation from patients with sepsis (4) .
Diagnostics that can distinguish sepsis from noninfectious inflammation are difficult to derive, as many of the cellular pathways that are activated in response to infections are also activated in response to tissue trauma and noninfectiousoverfit results (5, 6) . Furthermore, in an effort to increase statistical power, biomarker discovery is usually performed in a clinically homogeneous cohort using a single type of microarray. Although this homogeneous design does result in a greater statistical power, the results are less likely to remain true in different clinical cohorts using different laboratory techniques. As a result, multiple independent validations are necessary for any new classifier derived from high-throughput studies.
To the best of our knowledge, at the time of this writing, there are three gene expression diagnostics that have been specifically developed to separate patients with sepsis from those with noninfectious inflammation. Each hypothesizes that a conserved set of host genes in whole blood is transcriptionally regulated in response to infection. The three diagnostics are the 11-gene set hereafter referred to as the "Sepsis MetaScore" (SMS) (7) , the Fas apoptotic inhibitory molecule (FAIM) 3-to-placenta-specific (PLAC) 8 ratio (8) , and the Septicyte Lab (9) . In addition, there are now dozens of publicly available datasets examining patients with sepsis or acute infections. They span a broad range of clinical conditions, including different age groups, infection types, comorbid conditions, and control (noninfectious) conditions. This public resource can thus be used to estimate the relative strengths and weaknesses of different diagnostics across an enormous number of patient samples. Here, we used all available public gene expression data to study and directly compare the diagnostic power of the three sepsis gene expression diagnostics.
METHODS
We completed a systematic search on December 10, 2015, of two public gene expression repositories (National Institutes of Health Gene Expression Omnibus and European Bioinformatics Institute ArrayExpress) using the following terms: sepsis, systemic inflammatory response syndrome (SIRS), pneumonia, trauma, ICU, infection, acute, shock, and surgery. We automatically excluded nonmicroarray, nonhuman data. Next, using the abstracts of the corresponding articles for screening, we eliminated nonclinical and nontime-matched datasets. Finally, we selected only datasets performed in whole blood, total blood leukocytes, or neutrophils (since neutrophils make up ~ 75% of WBCs during acute inflammation in adults [7] ). The remaining datasets were then sorted according to whether the reference group (compared to sepsis) was healthy controls or noninfected SIRS patients. A schematic diagram is shown in Fig. 1 . In addition to the above cohorts, we included the two longitudinal trauma cohorts from the Inflammation and Host Response to Injury (Glue Grant) cohorts, as described previously (7) . Cohorts from the same study run on different types of microarrays were treated as independent. Use of the Glue Grant was approved by both the Glue Grant consortium and the Stanford University institutional review board (protocol 29798). All other data are publicly available and so exempt from review.
Given the limited phenotype data available in the public domain, it was impossible for us to review determinations of infection. Thus, in all cases, we accepted the determination of infection supplied by the original study authors, including cases of "clinical sepsis," where no pathogen was confirmed but independent adjudicators retrospectively classified a patient as likely having an infection.
We have included some patients at multiple timepoints both to serve as controls and to ensure a robust diagnostic effect. The duplicated patients are as follows: 1) Glue Grant noninfected controls: all patients are duplicated over time; in other words, in the noninfected class, the same group of patients serve as controls for the infected patients at later timepoints. As we previously described (7), this is necessary to prevent bias due to change in gene expression over time of recovery. 2) In cohort GSE68310, patients were followed over time for a full year; we have included controls from both initial baseline and following seasonal baseline. 3) Four cohorts included multiple timepoints within 48 hours of admission: GSE20346, GSE40012, GSE57065, and GSE68310. Microarray data exist in both "raw" form (fluorescence intensities) and "normalized" form (corrected for background and chip effects). Different normalization techniques between datasets can lead to extra technical differences (10) . Here, we renormalized all datasets for which raw data were available using standardized techniques to minimize technical variation. Affymetrix arrays were renormalized using guanine-cytosine robust multiarray analysis (RMA) (on arrays with perfect match probes) or RMA (11) . Illumina, Agilent, General Electric Healthcare, and other commercial arrays were renormalized via normal-exponential background correction followed by quantile normalization. Custom arrays were not renormalized. All data were log 2 transformed. Probes were summarized to genes within datasets using a fixed effects model (10) .
A literature search was conducted for gene expression signatures specifically optimized for diagnosis of sepsis as compared to noninfected hospitalized patients. The 11-gene SMS is calculated according to the following formula (7):
The FAIM3-to-PLAC8 ratio is calculated as follows: FAIM3/ PLAC8 (we also added a negative coefficient to the score so that it would be increasing in the presence of infection and decreasing in controls) (8) . The Septicyte Lab is calculated as follows: (PLAC8 + lysosomal-associated membrane protein 1) -(phospholipase A2 group VII [PLA2G7] + carcinoembryonic antigen related cell adhesion molecule [CEACAM] 4) (9). The derivation of each score can be found in its corresponding original article. In all cases, the calculations are performed on log 2 -transformed data. The resulting scores were tested for diagnostic power as measured by the area under the receiver operating characteristic curves (AUC). Datasets for which any of the sepsis scores could not be calculated (either all up-regulated or all down-regulated genes were missing) were excluded from final results. For a given comparison (e.g., noninfectious SIRS vs sepsis at admission), mean AUCs were calculated both for all datasets of that type and for only nondiscovery datasets, since discovery datasets overestimate diagnostic power as compared to independent validation. Finally, we compared the overlapping validation sets for each diagnostic score with paired-sample t tests (e.g., the SMS and the FAIM3-to-PLAC8 ratio were compared in their ability to diagnose sepsis in GSE74227, E-MEXP-3589, and the Glue Grant neutrophils, as these were the only cohorts that were validated for both datasets). To compare sensitivity and specificity at equal points, we used the R package OptimalCutpoints (11) to select the closest attainable sensitivity to 95% for each dataset. As this sensitivity, the maximum specificity was recorded. The same paired-sample t test procedure was used to compare specificity levels between scores.
The patient samples in GSE28750 (12) (n = 21) were reassayed in the later dataset GSE74224 (9) (n = 105), though the two datasets were run using different microarray types (Affymetrix HG 2.0 vs Affymetrix Exon 1.0 ST). As a result, GSE28750 is not included in the validation calculation for the Septicyte Lab (discovered in GSE74224), whereas in computing the validation mean for the SMS, the AUC in GSE74224 was penalized to account for the fact that 20% of the GSE74224 patients were present in discovery ([penalized AUC × 0.8 + actual AUC in GSE28750 × 0.2] = actual AUC).
To test confounding by infection type, each dataset was screened for the presence of both 1) Gram-positive and Gramnegative infections, or 2) bacterial and viral infections. Cases of coinfection were not included in the confounding comparisons. In each cohort that included two classes of interest, the diagnostic scores between classes were compared via the Wilcoxon signed rank test. Then, raw scores across cohorts were compared using paired-sample t tests.
Meta-analysis was performed as previously described (7). Briefly, differential gene expression between patients with noninfectious inflammation and sepsis was summarized within datasets using Hedges' g and then compared between datasets using a DerSimonian-Laird random effects model.
All analyses were performed using the R statistical computing language (R Foundation for Statistical Computing, Vienna, Austria; http://www.R-project.org/). Significance tests were always two tailed. Code and data to recreate the admission noninfectious SIRS versus sepsis comparisons for the examined gene sets are available at http://khatrilab.stanford.edu/sepsis. The uploaded data are in the renormalized form used here. Glue Grant data are available to researchers who have been approved by the Glue Grant consortium; instructions are on the website.
RESULTS
We performed a systematic search of public gene expression databases ( Fig. 1) , and also we used the two independent Glue Grant trauma cohorts, broken up into time-matched bins of never-infected patients and patients within ± 24 hours of diagnosis of sepsis, as previously described (7). This yielded a total of 39 cohorts that matched criteria, composed of 3,241 samples from 2,604 patients (8, 9, .
The robustness and reproducibility of each of the three sepsis scores depends on robust and reproducible change in expression for each of their constituent genes. Therefore, we explored how consistently individual genes in each of the three tests changed across 12 whole blood cohorts comparing noninfected SIRS/trauma patients to sepsis patients. Our meta-analysis of these datasets revealed that each of the 16 genes included in any of the three gene scores (except CEACAM4) changed in the hypothesized direction (false discovery rate < 5%; Fig. 2 ; and Table S1, Supplemental Digital Content 1, http://links.lww.com/CCM/C121). Notably, CEACAM4, one of the genes in the Septicyte Lab, was significantly down-regulated only in its corresponding discovery cohort (Fig. 2) .
Next, we divided the datasets into two broad types of comparison: patients with noninfectious SIRS or trauma versus sepsis or acute infections ( Table 1; and Table S2 , Supplemental Digital Content 1, http://links.lww.com/CCM/C121) and healthy controls versus patients with sepsis or acute infection ( Table 2; and Table S3 , Supplemental Digital Content 1, http://links.lww.com/CCM/C121). For both of these types of Forest plots for all genes used in any of the three scores, tested in all admission noninfectious systemic inflammatory response syndrome (SIRS) versus sepsis datasets. Genes are organized by gene set. The x-axes represent standardized mean difference between noninfectious SIRS versus sepsis samples, computed as Hedges' g, in log 2 scale. The size of the black rectangles is inversely proportional to the se of mean in the study. Whiskers represent the 95% CI. The gray diamonds represent overall, combined mean difference for a given gene. Width of the gray diamonds represents the 95% CI of overall combined mean difference. BATF = basic leucine zipper ATF-like transcription factor, C3AR1 = complement component 3a receptor 1, C9orf95 = nicotinamide riboside kinase 1 (also known as NMRK1), CEACAM = carcinoembryonic antigen-related cell adhesion molecule, FAIM3 = Fas apoptotic inhibitory molecule 3, GNA15 = G protein subunit alpha 15, HLA-DPB1 = MHC class II antigen DPB1, KIAA1370 = family with sequence similarity 214 member A (also known as FAM214A), LAMP1 = lysosomal-associated membrane protein 1, MTCH1= mitochondrial carrier 1, PLAC8 = placenta-specific 8, PLA2G7 = phospholipase A2 group VII, RPGRIP1 = retinitis pigmentosa GTPase regulator interacting protein 1, TGFBI = transforming growth factor beta-induced, ZDHHC19 = zinc finger DHHC-type containing 19. comparison, we calculated both the overall mean AUC and the AUC when including only independent validation datasets; for each of the three signatures, we excluded their corresponding discovery datasets.
In the noninfectious SIRS/trauma versus sepsis datasets (16 cohorts, 1,148 samples from 835 patients; Table 1; and Table S2 , Supplemental Digital Content 1, http://links.lww.com/CCM/ C121), there were no significant differences in paired-sample t tests between the AUCs of the three gene expression diagnostic scores comparing overlapping validation datasets (all p > 0.1; Figs. S1 and S2, Supplemental Digital Content 2, http://links. lww.com/CCM/C122; legend, Supplemental Digital Content 3, http://links.lww.com/CCM/C123). When comparing the AUCs from all 16 cohorts (i.e., including the discovery cohorts), the SMS AUCs were significantly higher than those of the other two gene scores (both p < 0.05), with no significant difference between the FAIM3-to-PLAC8 ratio and the Septicyte Lab. However, these results do not necessarily point to better overall performance of the SMS, as the SMS used nine of these cohorts in discovery. The FAIM3-to-PLAC8 ratio showed decreased performance in GSE32707 and GSE40012, but as discussed previously, it is specifically designed for testing the presence of communityacquired pneumonia (CAP) and may not be generalizable to other forms of noninfectious inflammation (42, 43) . Finally, the Septicyte Lab had significantly reduced performance (AUC < 0.5) in separating both pediatric SIRS/sepsis patients and hospitalized chronic obstructive pulmonary disease patients with and without infections. It is possible that this reduction in AUC for the Septicyte Lab is due to the differences in clinical circumstances or microarray types compared to the initial discovery cohort for the Septicyte Lab. Since the receiver operating characteristic curve measures a large potential space, we also obtained the sensitivity closest to 95% for each test and recorded the maximum specificity at that level (Table S3 , Supplemental Digital Content 1, http:// links.lww.com/CCM/C121). At sensitivities near 95%, the mean validation specificities were 53%, 45%, and 38%, respectively, for the SMS, FAIM3-to-PLAC8 ratio, and Septicyte Lab. There were no significant differences in paired-sample t tests in validation specificities among the three scores.
We next examined datasets that compared healthy controls to patients with sepsis or acute infections (26 datasets, 2,417 samples from 2,075 patients; Table 2; and Table S4 , Supplemental Digital Content 1, http://links.lww.com/CCM/ C121). Most, but not all, of these patients had sepsis; however, it is reasonable to expect that a sepsis diagnostic should be able to distinguish most infections from healthy controls. Here, both the SMS and the FAIM3-to-PLAC8 ratio performed well, with mean validation AUCs of 0.96 ± 0.05 and 0.94 ± 0.09 (Table 2) . However, the Septicyte Lab had an AUC less than 0.7 in 12 cohorts (43% of all cohorts) composed of 1,562 samples (64% of total samples), resulting in a mean validation AUC equal to 0.71 ± 0.20 (Table 2) , significantly lower than both other scores (both p < 1e-5). Although there is no clinical need for a diagnostic to separate healthy controls from patients with sepsis, poor performance in this area may be indicative of deeper biases and may increase the risk of nongeneralizability.
An ideal sepsis diagnostic would not show varying performance depending on the type of infection present. In order to study whether any of the diagnostics is biased by pathogen, we searched through all of the included datasets to find those comparing patients with bacterial and viral infections, and those comparing Gram-positive and Gram-negative infections. We then compared both the diagnostic power (as compared to healthy controls) and raw score distributions by infection type (via paired-sample t test across cohorts). Score distributions that are consistently lower in one infection type may indicate decreased diagnostic performance for that type, even if a change in diagnostic performance is not detected as compared to healthy controls.
There were eight datasets that provided information about whether a patient had bacterial or viral infection. In general, there were few differences between the AUCs for bacterial and viral infections for any of the three scores (Table S5 , Supplemental Digital Content 1, http://links.lww.com/CCM/ C121); however, this may be due to small numbers and the relatively high AUCs in comparing these infections to healthy controls. Despite these caveats, both the SMS and the FAIM3-to-PLAC8 ratio showed higher raw mean scores in patients with bacterial infections as compared to viral infections (both p < 0.05) ( Table S6 , Supplemental Digital Content 1, http://links. lww.com/CCM/C121). The Septicyte Lab, in contrast, did not show a strong trend in comparing bacterial and viral infections.
There were nine datasets that provided information about whether a patient had Gram-positive and Gram-negative infection. The comparison of Gram-positive and Gram-negative infections revealed small differences in AUC for both the SMS and the FAIM3-to-PLAC8 ratio; the Septicyte Lab showed greater variability, but this may be due to a high variability in diagnostic performance versus healthy controls rather than differences between Gram-positive and Gram-negative infections (Table S7 , Supplemental Digital Content 1, http://links.lww. com/CCM/C121). None of the three tests had raw scores that were significantly different overall according to Gram status, though the SMS showed a trend toward higher scores in Gramnegative infections (p = 0.055; Table S8 , Supplemental Digital Content 1, http://links.lww.com/CCM/C121).
DISCUSSION
Here, we compared three sepsis gene expression diagnostics (the SMS, the FAIM3-to-PLAC8 ratio, and the Septicyte Lab) in all available time-matched, whole blood clinical sepsis datasets. There were no significant differences among the distribution of AUCs comparing all validation noninfectious SIRS/trauma and sepsis datasets. However, in four of these cohorts, the FAIM3-to-PLAC8 ratio and the Septicyte Lab showed AUCs less than 0.7, showing a need for further prospective testing of all three scores. Notably, the Septicyte Lab also had significantly reduced performance in validation comparing healthy controls to patients with sepsis or acute infections, showing AUCs less than 0.7 in 43% of these cohorts. However, the Septicyte Lab was initially validated in a large, independent cohort of patients from the Molecular Diagnosis and Risk Stratification of Sepsis consortium using targeted quantitative PCR (qPCR) and showed an overall validation AUC of 0.88 (9); thus, the reduced performance in our analysis may be indicative of either differences in clinical conditions, difference in technology, or both. Meta-analysis shows that CEACAM4 (one of the four genes in the Septicyte Lab) was down-regulated only in its discovery cohort, which may be contributing to the relatively worse generalizability.
There is evidence of higher scores in bacterial infection as opposed to viral infection for the SMS and the FAIM3-to-PLAC8 ratio, although the Septicyte Lab showed no significant differences. There were no significant differences in Gram-negative as opposed to Gram-positive infections for any of the three scores. However, the differing pathogen types were not matched for illness severity, age, gender, or other clinical confounders in their individual datasets; hence, these trends must be interpreted with caution. For instance, if bacterial infections were generally more severe than viral infections and Gram negative generally more severe than Gram positive, then these scores might point to a confounding by severity. Still, when used in clinical practice, patients will not be part of a matched cohort, and the differences in bacterial and viral illness found here are worthy of further investigation. Further testing against all confounders will be necessary.
Previously, the SMS was validated in the Glue Grant neutrophils cohort and in a subset of the healthy versus infections cohorts (7) . In the additional cohorts tested here, the SMS continues to show results similar to prior validation. The FAIM3-to-PLAC8 ratio was validated in some of these data in a follow-up publication (44) , though the authors pointed out that their gene set was initially designed for a very narrow question of determining the presence of CAP in patients admitted to the ICU suspected of having CAP (43) . The Septicyte Lab was tested in cohort E-TABM-1548 (9), but we have previously shown that because of expected changes in the baseline gene expression profile due to recovery from surgery, it is not appropriate to use for testing sepsis diagnostics (7) .
The fact that the public data are not used more often for validation of new diagnostics may reflect the difficulty and knowledge curve that some researchers face in accessing and using these data. Given this difficulty, we have provided a handcurated, unified repository of these data, along with an R script to easily apply a classifier of interest to the datasets (http:// khatrilab.stanford.edu/sepsis). We recommend a practice that any new gene expression classifiers for sepsis should be tested in these data to allow for easy benchmarking and comparison between classifiers. We recognize that the simple measure of the AUC does not account for all potential measures of clinical utility, and that a score that repeatedly performs well in a single clinical area can still have great clinical utility even if it fails in a different clinical area. Nevertheless, it is important to elucidate the strengths and weaknesses of any new sepsis diagnostic in order to help focus resources on applications that show the most promise.
In all datasets used here, we accepted the determination of infections assigned by the original study authors. A true positive (such as Gram-negative bacteremia) is often easy to assign from clinical data. However, the lack of gold standard in determining the presence of infection can make the culture-negative patient difficult to correctly diagnose. For instance, if a culture-negative patient still clinically classified as "septic" were to show very low probabilities of infection in all three gene scores (or viceversa), it is not immediately clear which designation would be correct. When such tests are ready for clinical use, treating clinicians will need to integrate clinical judgment with test results to ensure patient safety.
Another issue in translating these tests to practice is measurement platform. Accurate and rapid quantitation of gene expression is traditionally done with qPCR, which can be optimized to return in a couple of hours for a limited target set. Commercial optimization could take many potential forms; the goal will be a rapid sample-to-answer system that can give a clear, interpretable outcome, perhaps as a range of likelihood of infection. We conclude from the data presented here that these engineering problems are worth solving, given the relatively good performance of these tests at detecting the presence of infection.
Each of the diagnostic gene sets tested here has both strengths and weaknesses. In general, for any sepsis diagnostic to become useful clinically, it must retain good diagnostic power in a broad range of patient settings in its final form. Public microarray data allow for head-to-head comparisons of different gene expression diagnostics but may underestimate the diagnostic performance of any test compared to using a targeted assay. Thus, further prospective validation of any gene set will be needed prior to their application in clinical practice; such clinical trials will be most effective by calculating not just the AUC of the new diagnostics, but rather the net reclassification of those data given the circumstances at the time. The ultimate goal would be a randomized interventional trial to assess the effect of the host diagnostic on patient outcome; this will likely have to wait until an appropriate platform is available. Given the increasing accuracy of molecular profiling of the host response to infections, these tests will likely become a valuable part of the clinical toolset in diagnosing, treating, and potentially preventing sepsis.
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